Optimisation of a primary human CAR‐NK cell manufacturing pipeline
Open Access
- 1 January 2024
- journal article
- research article
- Published by Wiley in Clinical & Translational Immunology
- Vol. 13 (5) , e1507
Abstract
Objectives: Autologous chimeric antigen receptor (CAR) T‐cell therapy of B‐cell malignancies achieves long‐term disease remission in a high fraction of patients and has triggered intense research into translating this successful approach into additional cancer types. However, the complex logistics involved in autologous CAR‐T manufacturing, the compromised fitness of patient‐derived T cells, the high rates of serious toxicities and the overall cost involved with product manufacturing and hospitalisation have driven innovation to overcome such hurdles. One alternative approach is the use of allogeneic natural killer (NK) cells as a source for CAR‐NK cell therapy. However, this source has traditionally faced numerous manufacturing challenges.Methods: To address this, we have developed an optimised expansion and transduction protocol for primary human NK cells primed for manufacturing scaling and clinical evaluation. We have performed an in‐depth comparison of primary human NK cell sources as a starting material by characterising their phenotype, functionality, expansion potential and transduction efficiency at crucial timepoints of our CAR‐NK manufacturing pipeline.Results: We identified adult peripheral blood‐derived NK cells to be the superior source for generating a CAR‐NK cell product because of a higher maximum yield of CAR‐expressing NK cells combined with potent natural, as well as CAR‐mediated anti‐tumor effector functions.Conclusions: Our optimised manufacturing pipeline dramatically improves lentiviral transduction efficiency of primary human NK cells. We conclude that the exponential expansion pre‐ and post‐transduction and high on‐target cytotoxicity make peripheral blood‐derived NK cells a feasible and attractive CAR‐NK cell product for clinical utility.Keywords
This publication has 57 references indexed in Scilit:
- Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cellsCytotherapy, 2009
- Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective StudyTransplantation and Cellular Therapy, 2008
- NK Cell Maturation and Peripheral Homeostasis Is Associated with KLRG1 Up-RegulationThe Journal of Immunology, 2007
- CCR5 Usage by CCL5 Induces a Selective Leukocyte Recruitment in Human Skin Xenografts In VivoJournal of Investigative Dermatology, 2006
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancerBlood, 2005
- Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic TransplantsScience, 2002
- Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent miceProceedings of the National Academy of Sciences, 1998
- Expression and Function of Low-Density Lipoprotein Receptors in CD3−CD16+CD56+Cells: Effect of Interleukin 2Cellular Immunology, 1996
- Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.1994
- Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.Journal of Clinical Investigation, 1991